Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade
Proceedings of the National Academy of Sciences · 24.03.2026 · 123 (12)
DOI: 10.1073/pnas.2532814123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 20.03.2026. Verfasst von Evan R Abt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095. Hauptthemen laut MEDLINE: E2F3 Transcription Factor, Pyrimidines, Synthetic Lethal Mutations, Retinoblastoma Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
Small cell carcinoma is a highly lethal cancer variant often found with neuroendocrine (NE) features, as exemplified by small cell lung cancer and small cell NE prostate cancer (SCPC). A genome-wide CRISPR dependency screen using SCPC models generated through human prostate cell transformation identifies a requirement for the transcription factor E2F3. E2F3 dependency is linked to RB inactivation, a near universal occurrence across small cell cancers. The requirement for E2F3 is shared by RB-deficient cells originating from the prostate, lung, and adnexa. In RB-deficient cancer cells, E2F3 inhibition restrains cell cycle progression, proliferation, and tumor growth in vivo. Inhibition of de novo pyrimidine synthesis limits E2F3 expression and suppresses small cell carcinoma proliferation in culture. Directly or indirectly targeting E2F3 to leverage a pan-cancer synthetic lethality resulting from RB inactivation represents a potential treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
- Jonsson Comprehensive Cancer Center, The David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
- Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
- Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095.
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
- Department of Pharmacology, Physiology and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
ORCID-Profile: Evan R Abt, Caius G Radu, Thomas G Graeber, Owen N Witte
Förderung
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Abt, E. R., Wang, L., Varuzhanyan, G., Freeland, J., He, T., Peña-Garcia, G. M., Ruegg, L., McLaughlin, J., Cheng, D., Balanis, N. G., Chen, C. C., Xu, Y., Xing, Y., Memarzadeh, S., Radu, C. G., Graeber, T. G., & Witte, O. N. (2026). Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. Proceedings of the National Academy of Sciences, 123(12). https://doi.org/10.1073/pnas.2532814123
Vancouver
Abt ER, Wang L, Varuzhanyan G, Freeland J, He T, Peña-Garcia GM, et al. Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. Proceedings of the National Academy of Sciences. 2026;123(12). doi:10.1073/pnas.2532814123
BibTeX
@article{Abt2026,
author = {Abt, Evan R and Wang, Liang and Varuzhanyan, Grigor and Freeland, Jack and He, Tian and Peña-Garcia, Guadalupe M and Ruegg, Lauryn and McLaughlin, Jami and Cheng, Donghui and Balanis, Nikolas G and Chen, Chia-Chun and Xu, Yang and Xing, Yi and Memarzadeh, Sanaz and Radu, Caius G and Graeber, Thomas G and Witte, Owen N},
title = {Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {12},
doi = {10.1073/pnas.2532814123}
}
EUVIMED